Waldenström巨球蛋白血症(WM)是一种罕见的淋巴浆细胞性淋巴瘤,可能使个体易患继发性恶性肿瘤(SM)。监视,流行病学,和最终结果(SEER)数据库是美国癌症患者的综合注册表,报告了一系列广泛的人口统计学变量。使用SEER-18数据集,分析2000年至2018年的患者,我们旨在评估WM患者中SMs的发生率。患者特征,如性别,年龄,种族,并确定了延迟,并计算各自的标准化发病率比(SIR)和绝对超额危险度(AERs),以与普通人群进行比较.在确定的4112名符合条件的WM患者中,在699例(17%)患者中报告了SM。开发SM的总体风险,第二原发恶性肿瘤,与普通人群相比,WM患者的继发性血液恶性肿瘤明显更高。我们的研究结果表明,WM患者相对于普通人群有53%的SMs风险。AER为102.69/10,000。虽然确切的机制还不清楚,SM发育的风险可能是由于遗传易感性,免疫失调,或治疗诱导的免疫抑制。
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma which may predispose individuals to development of secondary malignancies (SMs). The Surveillance, Epidemiology, and End Results (SEER) database is a comprehensive registry of cancer patients in the United States reporting on a wide set of demographic variables. Using the SEER-18 dataset, analyzing patients from 2000 to 2018, we aimed to assess the incidence of SMs in WM patients. Patient characteristics such as gender, age, race, and latency were identified, and respective standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated to compare to the general population. Of the 4,112 eligible WM patients identified, SMs were reported in 699 (17%) patients. The overall risk of developing SM, second primary malignancy, and secondary hematological malignancy was significantly higher in WM patients compared to the general population. Our findings show that WM patients had a 53% higher risk of SMs relative to the general population, and an AER of 102.69 per 10,000. Although the exact mechanism is unclear, the risk of SM development may be due to genetic predisposition, immune dysregulation, or treatment-induced immune suppression.